Tecentriq meets in Phase III lung cancer study

Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit said Tecentriq atezolizumab ( MPDL3280A) met the co-primary endpoints in the open-label Phase III OAK study of the PD-L1 inhibitor as a second-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients whose disease has progressed on or after platinum-based chemotherapy.

Tecentriq significantly improved overall survival (OS) vs. docetaxel in all NSCLC patients enrolled in the study, regardless of PD-L1 status, a co-primary endpoint. The drug also significantly improved OS in a subgroup of patients with at least 1% PD-L1 expression in tumor or tumor-infiltrating immune cells based on a Roche immunohistochemistry test, the other co-primary endpoint. ...